Clinical

Articles

Epcoritamab monotherapy yielded positive results in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and should be studied further, according to investigators.

Epcoritamab Monotherapy Demonstrates Promising Early Findings for Patients With R/R B-Cell non-Hodgkin Lymphoma

Videos

The combination of zanubrutinib and zandelisib for the treatment of B-cell malignancies may offer patients the opportunity to receive therapy that is not based around chemotherapy.

John Pagel, MD, PhD, Discusses Key Takeaways of a Trial Examining Zanubrutinib Plus Zandelisib in B-Cell Malignancies

Zanubrutinib and zandelisib combination appears to be a well-tolerated regimen for the treatment of B-cell malignancies, according to early study results. 

John Pagel, MD, PhD, Discusses Dosing Regimens and Toxicity Associated With Zanubrutinib and Zandelisib

Patients with relapsed or regractory B-cell malignancies who were treated with zanubrutinib and zandelisib demonstrated high response rates across several treatment cohorts. 

John Pagel, MD, PhD, on Promising Responses Seen With Zanubrutinib Plus Zandelisib for B-Cell Malignancies

Minority patients with aggressive B-cell lymphoma experienced equitable outcomes through more accessible care and the use of the nurse navigators.

Minority Populations With Aggressive B-Cell Lymphoma Achieved Equitable Estimated Survival Through Equal Access to Care and Nurse Navigation 

Low-dose rotational total skin electron beam therapy helped to improve skin-related quality of life and yielded promising responses among patients with mycosis fungoides.

Promising Responses, Improved Skin-Related QoL Observed With Low-Dose Skin Electron Beam Therapy for Mycosis Fungoides

Pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin appears to be a successful bridging regimen for patients with relapsed/refractory classical Hodgkin lymphoma. 

Second-Line Pembrolizumab Plus Gemcitabine, Vinorelbine, And Liposomal Doxorubicin Demonstrates Efficacy in R/R Classical Hodgkin Lymphoma

Patients with relapsed/refractory Waldenströms macroglobulinemia benefited from treatment with ixazomib, rituximab, and dexamethasone and maintained a tolerable safety profile.

Ixazomib, Rituximab, and Dexamethasone Combo Demonstrates Promising Efficacy in R/R Waldenströms Macroglobulinemia

FT596 and FT516 natural killer cell products elicited promising responses in a population of patients with B-cell lymphoma.

FT596 and FT516 Off-the-shelf, iPSC-derived NK Cell Products Shows Promise in B-Cell Lymphoma

The accelerated approval status for romidepsin for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma has been withdrawn following the results of the confirmatory phase 3 Ro-CHOP trial.

Lymphoma | Topics